Hematology

Publications

A., P; G., T; L., T; B., S; T., W; P., O; L., S; P., M; S., S; T., L; et al. O-01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB-SAHARAN AFRICA: THE REACH EXPERIENCE. HemaSphere. 2022; 6:01.

Abu Ata, N; Hammill, AM; Merrow, AC. Neonatal vascular anomalies manifesting as soft-tissue masses. Pediatric Radiology: roentgenology, nuclear medicine, ultrasonics, CT, MRI. 2022; 52:786-801.

Appiah-Kubi, A; Jacob, SA; Heeney, MM; Brown, C; Creary, SE; Hollenkamp, CR; Meier, ER; Niss, O; Piccone, CM; Quarmyne, M; et al. Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial. Blood. 2022; 140:5416-5417.

Aukrust, CG; Parikh, K; Smart, LR; Mdala, I; Fjeld, HE; Lubuulwa, J; Makene, AM; Härtl, R; Winkler, AS. Pediatric Hydrocephalus in Northwest Tanzania: A Descriptive Cross-Sectional Study of Clinical Characteristics and Early Surgical Outcomes from the Bugando Medical Centre. World Neurosurgery. 2022; 161:e339-e346.

Bello, A; Casanova, A; Arias, A; Kalfa, T; Kussick, S. Poster: MPN-024 Hypereosinophilic Syndrome: A Catastrophic Pediatric Case. Clinical Lymphoma, Myeloma and Leukemia. 2022; 22:s160.

Bello, A; Casanova, A; Arias, A; Kalfa, T; Kussick, S. MPN-024 Hypereosinophilic Syndrome: A Catastrophic Pediatric Case. Clinical Lymphoma, Myeloma and Leukemia. 2022; 22 Suppl 2:S322.

Berntorp, E; LeBeau, P; Ragni, MV; Borhany, M; Abajas, YL; Tarantino, MD; Holstein, K; Croteau, SE; Liesner, R; Tarango, C; et al. Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain. Haemophilia. 2022; 28:453-461.

Blei, F; Adams, D; Brandao, LR; Trenor, C; Iacobas, I; Hammill, A. Forward: Welcome to the Special Issue on Vascular Anomalies. Pediatric Blood and Cancer. 2022; 69 Suppl 3:e29796.

Boucher, AA; Francisco, BJ; Pfeiffer, A; Martin, M; Martin, J; Shova, A; Nathan, JD; Tiao, GM; Luchtman-Jones, L. Urinary 11-dehydrothromboxane B2 aspirin efficacy testing is sensitive to perioperative inflammation in pediatric solid-organ transplant patients. Pediatric Blood and Cancer. 2022; 69:e29413.

Cantrell, R; Palumbo, JS. Hemostasis and tumor immunity. Research and Practice in Thrombosis and Haemostasis. 2022; 6:e12728.

Cantrell, R; Rosenfeldt, L; Sharma, BK; Gourley, B; Revenko, A; Monia, B; Palumbo, J. The role of the Thrombin/PAR axis in modulating CD8+ T cell anti-tumor immunity. Journal of immunology (Baltimore, Md. : 1950). 2022; 208:121.12.

Carpenter, SL; Chandler, M; Guerrera, MF; Malec, L; Manuel, M; Recht, M; Reiss, U; Sidonio, Jr., RF; Tarango, C; Van den Berg, M; et al. U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics. Blood. 2022; 140:63-64.

Carter Febres, ME; Fenchel, ME; Pomales, J; Tarango, C; Mullins, ES. Obesity and Race As Determinates of Plasma Von Willebrand and Factor VIII Levels. Blood. 2022; 140:5593-5594.

Coleman, KC; McKinley, K; Ellison, A; Brandow, AM; Nielsen, B; Cook, L; Alpern, E; Hariharan, S; Topoz, I; Wurtz, M; et al. Return Visit Rates after an Emergency Department Treat-and-Release Visit for Children with Sickle Cell Pain Episodes. Blood. 2022; 140:5418-5419.

Dong, M; Good, A; Vinks, AA; Ware, RE; McGann, PT. Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT). Blood. 2022; 140:8168-8169.

Dong, M; Sadaf, A; Vinks, AA; Ware, RE; Quinn, CT. Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis. Blood. 2022; 140:8256-8257.

Filuta, A; Amezcua, PK; Chang, W; Biagini, J; Kroner, J; He, H; Grashel, B; Almasri, C; Martin, L; Palumbo, JS; et al. LB1033 Thrombin contributes to atopic dermatitis pathogenesis and staphylococcus aureus skin colonization in children. Journal of Investigative Dermatology. 2022; 142:b36.

Forsyth, S; Schroeder, P; Geib, J; Vrishabhendra, L; Konstantinidis, DG; LaSalvia, K; Ribadeneira, MD; Wu, E; Kelly, P; Kalfa, TA. Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. Clinical Pharmacology in Drug Development. 2022; 11:654-665.

Gibson, SJ; Kalfa, TA; DeStefano, CB. Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis. American Journal of Hematology. 2022; 97:1384-1385.

Goldenberg, NA; Kittelson, JM; Abshire, TC; Bonaca, M; Casella, JF; Dale, RA; Halperin, JL; Hamblin, F; Kessler, CM; Manco-Johnson, MJ; et al. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. Journal of the American Medical Association. 2022; 327:129-137.

Green, NS; Zapfel, A; Nnodu, OE; Franklin, P; Tubman, VN; Chirande, L; Kiyaga, C; Chunda-Liyoka, C; Awuonda, B; Ohene-Frempong, K; et al. The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology. Blood Advances. 2022; 6:6187-6197.

Hildenbrand, AK; King, AA; Mara, CA; Johnson, Y; Shook, LM; Whitacre, C; Britto, MT; Quinn, CT; Brinkman, W; Hackworth, R; et al. Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia. Blood. 2022; 140:10857-10859.

Hood, AM; Crosby, LE; Hanson, E; Shook, LM; Lebensburger, JD; Madan-Swain, A; Miller, MM; Trost, Z. The influence of perceived racial bias and health-related stigma on quality of life among children with sickle cell disease. Ethnicity and Health. 2022; 27:833-846.

Juang, LJ; Hur, WS; Silva, LM; Strilchuk, AW; Francisco, B; Leung, J; Robertson, MK; Groeneveld, DJ; La Prairie, B; Chun, EM; et al. Suppression of fibrin(ogen)-driven pathologies in disease models through controlled knockdown by lipid nanoparticle delivery of siRNA. Blood. 2022; 139:1302-1311.

Kaj-Carbaidwala, B; Bernieh, A; Russi, AE; Miethke, AG; Abu-El-Haija, M; Trout, AT; Gupta, A; Ricci, KW; Nathan, JD. Total pancreatectomy with islet autotransplantation in a child with pancreatic kaposiform hemangioendothelioma. Journal of Pediatric Surgery Case Reports. 2022; 81:102266.

Karkoska, K; Pfeiffer, A; Beebe, DW; Quinn, CT; Niss, O; McGann, PT. Early hydroxyurea use is neuroprotective in children with sickle cell anemia. American Journal of Hematology. 2022; 97:E368-E370.

Kharnaf, M; Hogue, S; Wilkes, Z; Reagor, JA; Leino, DG; Gourley, B; Rosenfeldt, L; Ma, Q; Devarajan, P; Palumbo, JS; et al. A Murine Model of Veno-Arterial Extracorporeal Membrane Oxygenation. ASAIO Journal. 2022; 68:e243-e250.

Kumar, R; Dunn, AL; Schneiderman, JE; Gonzales, A; Bouskill, V; Widener, P; Stanek, J; Pluthero, FG; Waller, A; Tarango, C; et al. Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022; 140:1156-1166.

L., S; M., C; A., P; T., H; K., M; E., A; R., W. O-12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW-RESOURCE SETTINGS. HemaSphere. 2022; 6:07-08.

Lynch, DR; Stringham, EN; Zhang, B; Balbin-Cuesta, G; Curtis, BR; Palumbo, JS; Greineder, CF; Tourdot, BE. Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies. Blood Advances. 2022; 6:4645-4656.

M., T; R., B; R., H; M., I; I., O; T., K; F., K; J., G; P., S; E., WU; et al. O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH. HemaSphere. 2022; 6:02-03.

Macharia, AW; Mochamah, G; Makale, J; Howard, T; Mturi, N; Olupot-Olupot, P; Färnert, A; Ware, RE; Williams, TN. Case Report: β-thalassemia major on the East African coast. Wellcome Open Research. 2022; 7:188.

Makani, J; Cavazzana, M; Gupta, K; Nnodu, O; Odame, I; Tshilolo, L; Ware, R; Luzzatto, L. Blood diseases in Africa: Redressing unjust disparities is an urgent unmet need. American Journal of Hematology. 2022; 97:1505-1506.

McGrady, ME; Todd, K; Ignjatovic, V; Jones, S; Rizzi, M; Luchtman-Jones, L; Thornburg, C. Results of an international survey on adherence with anticoagulation in children, adolescents, and young adults: Communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis. 2022; 20:1720-1728.

Mwazyunga, Z; Ambrose, EE; Kayange, N; Bakalemwa, R; Kidenya, B; Smart, LR; Hokororo, A. Health Related Quality of Life among Children with Sickle Cell Anaemia in Northwestern Tanzania. 2022; 12:11-28.

Nima, MK; Mukherjee, A; Sazed, SA; Hossainey, MR H; Phru, CS; Johora, FT; Safeukui, I; Saha, A; Khan, AA; Marma, AS P; et al. Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. Editor, Bhanot P. mBio. 2022; 13:e0344421.

Niss, O; Quinn, CT. Chapter 3 Classification and diagnosis of anemia in children and neonates. Lanzkowsky's Manual of Pediatric Hematology and Oncology. : Elsevier; Elsevier; 2022.

Noel, JG; Ramser, SW; Pitstick, L; Bonamer, JP; Mackenzie, B; Seu, KG; Kalfa, TA; Cancelas, JA; Gardner, JC. M-CSF supports medullary erythropoiesis and erythroid iron demand following burn injury through its activity on homeostatic iron recycling. Scientific Reports. 2022; 12:1235.

Noomuna, P; Hausman, JM; Sansoya, R; Kalfa, T; Risinger, M; Low, PS. Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2022; 36:e22360.

O'Brien, SH; Badawy, SM; Rotz, SJ; Shah, MD; Makarski, J; Bercovitz, RS; Hogan, MJ S; Luchtman-Jones, L; Panepinto, JA; Priola, GM; et al. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Blood Advances. 2022; 6:679-685.

Palumbo, JS. Crosstalk between hemostasis and immunity in cancer pathogenesis. Thrombosis Research. 2022; 213 Suppl 1:S3-S7.

Palumbo, JS; Lensing, AW A; Brandão, LR; Hooimeijer, HL; Kenet, G; van Ommen, H; Pap, AF; Majumder, M; Kubitza, D; Thelen, K; et al. Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Advances. 2022; 6:5821-5828.

Power-Hays, A; Dandoy, CE; Lorts, A; Perentesis, JP; Unaka, N; Ware, RE; McGann, PT. US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Pediatric Blood and Cancer. 2022; 69:e29679.

Quinn, CT; Ware, RE. Reproductive equity: preserve the reserve. Blood. 2022; 139:963-965.

Quinn, CT; Ware, RE. New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?. Pediatric Blood and Cancer. 2022; 69:e29805.

R., N; A., C; C., B; M., G; D., D; R., W; R., O; C., J. PI-08: HIGH DISEASE BURDEN, MORBIDITY AND MORTALITY AMONG CHILDREN WITH SICKLE CELL ANAEMIA IN UGANDA. HemaSphere. 2022; 6:13.

Real, FJ; Hood, AM; Davis, D; Cruse, B; Klein, M; Johnson, Y; McTate, E; Brinkman, WB; Hackworth, R; Hackworth, K; et al. An Immersive Virtual Reality Curriculum for Pediatric Hematology Clinicians on Shared Decision-making for Hydroxyurea in Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology. 2022; 44:e799-e803.

Ricci, KW; Iacobas, I. How we approach the diagnosis and management of complex lymphatic anomalies. Pediatric Blood and Cancer. 2022; 69 Suppl 3:e28985.

Romano, L; Seu, KG; Papoin, J; Muench, DE; Konstantinidis, D; Olsson, A; Schlum, K; Chetal, K; Chasis, JA; Mohandas, N; et al. Erythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis. Blood. 2022; 140:1621-1634.

Sabulski, A; Nehus, EJ; Jodele, S; Ricci, K. Diagnostic Considerations in H1N1 Influenza-induced Thrombotic Microangiopathy. Journal of Pediatric Hematology/Oncology. 2022; 44:e237-e240.

Sadler, B; Minard, CG; Haller, G; Gurnett, CA; O'Brien, SH; Wheeler, A; Jain, S; Sharma, M; Zia, A; Kulkarni, R; et al. Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. Blood Advances. 2022; 6:420-428.

Schroeder, P; Fulzele, K; Forsyth, S; Ribadeneira, MD; Guichard, S; Wilker, E; Marshall, CG; Drake, A; Fessler, R; Konstantinidis, DG; et al. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. The Journal of pharmacology and experimental therapeutics. 2022; 380:210-219.

Setty, BA; Wusik, K; Hammill, AM. How we approach genetics in the diagnosis and management of vascular anomalies. Pediatric Blood and Cancer. 2022; 69 Suppl 3:e29320.

Seu, K; Voulgaridou, A; Stewart, M; Meznarich, J; Johnson, C; Junge, H; Mackenzie, B; Blanc, L; Cancelas, JA; Kalfa, TA. Dominant-Negative VPS4A Mutations Causing Congenital Dyserythropoietic Anemia Disrupt Iron Trafficking of Terminal Erythropoiesis. Blood. 2022; 140:8190-8191.

Shook, LM; Crosby, LE; Whitten-Shurney, W; Drawhorn, L; Yusuf, FI; Farrell, CB; Nelson, SC. A Health Equity Echo for Providers of Children and Adults with Sickle Cell Disease. Blood. 2022; 140:13141-13142.

Shook, LM; Farrell, CB; Mosley, C. Expanding a Regional Sickle Cell Disease Project ECHO® to Rapidly Disseminate COVID-19 Education. Advances in Medical Education and Practice. 2022; 13:443-447.

Sobreira, N; Yeom, S; Cohen, B; Weiss, C; Hammill, A; Comi, A. eP250: Molecular findings in patients with atypical Sturge-Weber syndrome. Genetics in Medicine. 2022; 24:s159.

T., C; A., LA L; R., B; T., K; J., K; J., B; C., T; K., W; S., S. P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere. 2022; 6:43-44.

Todd, KE; McGrady, ME; Starbuck, E; Previtera, M; Luchtman-Jones, L. A systematic review of adherence to anticoagulation regimens in pediatric patients. Pediatric Blood and Cancer. 2022; 69:e29698.

Tseng, SY; Gao, Z; Kalfa, TA; Ollberding, NJ; Tabbah, S; Keller, R; Cnota, JF. Altered erythropoiesis in newborns with congenital heart disease. Pediatric Research. 2022; 91:606-611.

Tu, Z; Fan, C; Davis, AK; Hu, M; Wang, C; Dandamudi, A; Seu, KG; Kalfa, TA; Lu, QR; Zheng, Y. Autism-associated chromatin remodeler CHD8 regulates erythroblast cytokinesis and fine-tunes the balance of Rho GTPase signaling. Cell Reports. 2022; 40:111072.

Voulgaridou, A; Elgammal, Y; Husami, A; Emberesh, S; Seu, K; Ramamoorthy, M; Trump, L; Barasa, N; Nelson, AS; Lorsbach, RB; et al. De Novo Germline DHX38 Variant Associated with Alternative Splicing of Multiple Transcripts in Iron-Related Pathways in a Patient with Atypical Congenital Dyserythropoietic Anemia with Ring Sideroblasts. Blood. 2022; 140:1234-1235.

Wagner, ML; Johnston, M; Jenkins, T; Palumbo, JS; Rymeski, BA. Use of thromboelastography in children on extracorporeal membrane oxygenation. Journal of Pediatric Surgery. 2022; 57:1056-1061.